Novocure Ltd

NASDAQ:NVCRUnited States

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Contact Information

Headquarters

No. 4 The Forum, Grenville StreetSAINT HELIER, Jersey JE2 4UF

Phone

153-475-6700

Fax

---

Executives

Executive Chairman of the Board

William Doyle

President, Chief Executive Officer, Director

Asaf Danziger

Chief Financial Officer

Ashley Cordova

Chief Operating Officer

Wilhelmus Groenhuysen

Chief Human Resource Officer

Michael Puri